Get the Stockscreener App
177.24
1.86%
3.14
Neurocrine Biosciences Inc stock is traded at $177.24, with a volume of 524.12K.
It is up +1.86% in the last 24 hours and up +8.21% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$174.10
Open:
$176.1
24h Volume:
524.12K
Relative Volume:
0.43
Market Cap:
$17.82B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
27.25
EPS:
6.5044
Net Cash Flow:
$831.30M
1W Performance:
+5.22%
1M Performance:
+8.21%
6M Performance:
+26.11%
1Y Performance:
+38.67%
1-Day Range:
$174.75
$178.75
1-Week Range:
$165.91
$178.75
52-Week Range:
$122.14
$178.75
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
177.22 | 17.52B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
16.99 | 52.99B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.815 | 43.25B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.71 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.50 | 31.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
561.00 | 23.60B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen - ChartMill
NBIXNeurocrine Biosciences Inc Options - Finviz
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders - Sahm
Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv - GuruFocus
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries - Yahoo Finance
Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia - Yahoo Finance
Neurocrine starts phase 2 trial of crinecerfont in infants with CAH - Investing.com
Neurocrine tests CRENESSITY in infants and toddlers with rare CAH - Stock Titan
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know - Yahoo Finance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup - ChartMill
Price to book forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares - Stock Titan
Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says - Moomoo
Price to book forward of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $208 - Moomoo
9,800-share Form 144 filed for NBIX (NASDAQ: NBIX) - Stock Titan
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day - The Globe and Mail
Neurocrine Biosciences stock hits all-time high at 169.62 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 169.62 USD - Investing.com
Bull of the Day: Neurocrine Biosciences (NBIX) - Zacks Investment Research
Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia
Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Enterprise value to EBITDA forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Costco Stock And 2 Low Risk Picks Built For Volatile Markets - simplywall.st
Neurocrine Biosciences, Inc. Actuals & Estimates (DUS:NB3) - TradingView
NBIX Forecast — Price Target — Prediction for 2027 - TradingView
NB3 Forecast — Price Target — Prediction for 2027 - TradingView
5 High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences Inc (NBIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Best Momentum Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework - ChartMill
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lippoldt Darin | Chief Legal Officer |
Jun 26 '26 |
Option Exercise |
81.49 |
200 |
16,298 |
54,929 |
| Lippoldt Darin | Chief Legal Officer |
Jun 29 '26 |
Sale |
170.16 |
9,800 |
1,667,579 |
54,729 |
| Lippoldt Darin | Chief Legal Officer |
Jun 26 '26 |
Sale |
169.56 |
200 |
33,913 |
54,729 |
1.16%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):